



KENNY C. GUINN  
Governor

STATE OF NEVADA  
DEPARTMENT OF HUMAN RESOURCES

**DIVISION OF HEALTH CARE FINANCING AND POLICY**

NEVADA MEDICAID

**NOTICE OF OPEN PUBLIC MEETING**

MICHAEL J. WILLDEN  
Director

CHARLES DUARTE  
Administrator

The Division of Health Care Financing and Policy ("DHCFP"), Pharmaceutical and Therapy Committee, will conduct a public meeting on **July 28, 2005** beginning at **1:00 p.m.** at the following location:

**CARSON CITY**  
**Legislative Building**  
**401 South Carson Street**  
**Room 2135**  
**Carson City**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-687-8228 or toll free at: 1-800-992-0900, ext. 43605 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

**Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.**

**Public comment may be limited to 3 minutes per person or per company/product at the discretion of the Chairperson.**

**AGENDA**

- I. Call to Order and Roll Call
- II. \*Review and Approval of April 28<sup>th</sup> meeting Minutes
- III. Public Comment
- IV. Drug Classes without Proposed Changes
  - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
    - 1. Antibiotics: Cephalosporins 2<sup>nd</sup> Generation
    - 2. Antibiotics: Cephalosporins 3<sup>rd</sup> Generation
    - 3. Antibiotics: Macrolides
    - 4. Antibiotics: Quinolones 3<sup>rd</sup> Generation
    - 5. Antiemetics: Oral, 5-HT3s
    - 6. Antifungals: Onychomycosis Agents
    - 7. Cardiovascular: Ace Inhibitors & Diuretic Combinations
    - 8. Cardiovascular: Angiotensins II Receptor Blockers & Diuretic Combination
    - 9. Cardiovascular: Beta Blockers
    - 10. Cardiovascular: Calcium Channel Blockers & ACEI Combinations
    - 11. Central Nervous System: ADHD/Stimulants/Non-Stimulants
    - 12. Erectile Dysfunction Agents
    - 13. Gastrointestinal Agents: H2RAs
    - 14. Gastrointestinal Agents: PPIs
    - 15. Glaucoma Agents: Beta-Blockers, Alpha adrenergics, Carbonic Anhydrase Inhibitors

1100 E. William Street, Suite 102, Carson City, Nevada 89701  
(775) 684-3600

16. Hepatitis C Agents
  17. Herpetic Antiviral Agents
  18. Leukotriene Modifiers
  19. Respiratory: Glucocorticoids, Inhalers
  20. Respiratory: Glucocorticoids, Nasal
  - B. \* Committee Discussion and Approval of Drug Classes without changes for the PDL
- V. Analgesics: Long Acting Narcotics
- A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VI. Antibiotics: Quinolones 2<sup>nd</sup> Generation
- A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VII. Antidepressants: Novel
- A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VIII. Antidepressants: SSRIs
- A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- IX. Antihistamines: 2<sup>nd</sup> Generation
- A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL

- X. Bone Ossification Agents: Biphosphonates
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XI. Cardiovascular: Lipotropics
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XII. Central Nervous System: Sedative, Hypnotics
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XIII. Glaucoma Agents-Postaglandins
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XIV. Respiratory: Anticholinergic Agents, Inhaled
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XV. Respiratory Agents: Beta-Adrenergic Agents, Long-Acting Inhaled
  - A. Public Comment
  - B. Drug Class Review Presentation – First Health Services
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy

- E.       \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XVI.    Respiratory Agents: Beta-Adrenergic Agents, Short-Acting Inhaled
  - A.       Public Comment
  - B.       Drug Class Review Presentation – First Health Services
  - C.       \*Committee Discussion and Action
    - 1.       Approve Clinical/Therapeutic Equivalency of Agents in Class
    - 2.       Identify Exclusions/Exceptions for Certain Patient Groups
  - D.       Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E.       \* Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XVII.    Review of Next Meeting Location, Date, and Time
- XVIII.   Public Comment
- XIX.     \*Adjournment

**\* Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

**Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([dhcftp@state.nv.us](mailto:dhcftp@state.nv.us)).**

**Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.**

**All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.**

**Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.**